SCHEMBL2972175

SCHEMBL2972175

CCN(CC)Cc1ccc(C(=O)Nc2cc(C(=O)Nc3cccc(N4CCOCC4)c3)ccc2C)cc1

nearest known ligand 0.60

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 16/20 0.60
SMO Q99835 1/20 0.55
SETD2 Q9BYW2 2/20 0.52
CSF1R P07333 2/20 0.50
LCK P06239 1/20 0.50
KDR P35968 1/20 0.50
MAP2K1 Q02750 1/20 0.50
HCK P08631 1/20 0.49
NR2C2 P49116 1/20 0.49
BTK Q06187 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6487809 0.94 MAPK14 (0.69) MAPK14SMOCSF1R
SCHEMBL7852826 0.93 MAPK14 (0.55) MAPK14SMOSETD2CSF1RLCK
SCHEMBL7809453 0.92 MAPK14 (0.57) MAPK14SMOSETD2
SCHEMBL27558565 0.91 MAPK1 (0.57) MAPK14SMOCSF1R
SCHEMBL2979099 0.85 MAPK14 (0.65) MAPK14SMOSETD2CSF1RLCK
SCHEMBL6977502 0.84 MAPK14 (0.56) MAPK14SMOCSF1RHCKNR2C2
SCHEMBL6477438 0.84 MAPK14 (0.67) MAPK14SMOCSF1R
SCHEMBL2972180 0.83 MAPK14 (0.55) MAPK14SMOSETD2CSF1RLCK
SCHEMBL2970434 0.82 MAPK14 (0.64) MAPK14SMOSETD2CSF1RLCK
SCHEMBL6975166 0.82 MAPK14 (0.65) MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1243724-C Amide derivatives which are useful as cell factor inhibitors ASTRA ZENECA LTD (SE) 2006-03-01 CN claimed
US-6821965-B1 IMPORTANT IN DISEASE OR MEDICAL CONDITIONS SUCH AS INFLAMMATION AND IMMUNOREGULATION ASTERZENECA AB (SE) 2004-11-23 US claimed
CN-1330631-A Amide derivatives which are useful as cell factor inhibitors ASTRA ZENECA LTD (SE) 2002-01-09 CN claimed
EP-1102743-A1 AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS AstraZeneca AB (SE) 2001-05-30 EP claimed
WO-2000007980-A1 AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS ASTRAZENECA AB (SE) 2000-02-17 WO claimed
US-7772432-B2 Amidobenzamide derivatives which are useful as cytokine inhibitors ASTRAZENECA AB (SE) 2010-08-10 US disclosed
US-20050038081-A1 Amidobenzamide derivatives which are useful as cytokine inhibitors ASTRAZENECA 2005-02-17 US disclosed
US-6821965-B1 IMPORTANT IN DISEASE OR MEDICAL CONDITIONS SUCH AS INFLAMMATION AND IMMUNOREGULATION ASTERZENECA AB (SE) 2004-11-23 US disclosed
CN-1330631-A Amide derivatives which are useful as cell factor inhibitors ASTRA ZENECA LTD (SE) 2002-01-09 CN disclosed
EP-1102743-A1 AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS AstraZeneca AB (SE) 2001-05-30 EP disclosed
WO-2000007980-A1 AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS ASTRAZENECA AB (SE) 2000-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038081-A1 Amidobenzamide derivatives which are useful as cytokine inhibitors IL6, IL6ST, IL2 MAPK14 1775/4885SMO 4706/4885SETD2 4091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.